Actonel provides vertebral fracture risk reduction in women with postmenopausal osteoporosis at risk for upper GI side effects.

(From Chemical Business NewsBase - Press Release)

Actonel (risedronate sodium tablets) reduces the risk of vertebral fracture up to 62% at one year in women with postmenopausal osteoporosis who are at risk for upper gastrointestinal (GI) side effects, according to new analyses presented at the American College of Rheumatology (ACR) annual meeting. Actonel is the only osteoporosis therapy proven to reduce the risk of vertebral fracture in just one year in postmenopausal women with osteoporosis. Additionally, Actonel is the only marketed bisphosphonate with upper GI events comparable to placebo in clinical trials that did not exclude patients at risk for GI side effects. Data for the analyses were obtained from subgroups of patients who participated in the treatment and placebo arms of the Actonel fracture clinical trials (VERT-NA, VERT-MN and HIP). In order to represent a real world population, the Actonel fracture clinical trials included patients at risk of upper GI side effects [those with past or active GI disease, taking H2 blockers, proton pump inhibitors (PPIs), non-steroidal anti-inflammatory drugs (NSAIDs) or aspirin]. Fracture rates between those on Actonel and placebo were compared for three subgroups: patients with preexisting GI disease, patients who reported using H2-blockers and/or PPIs and ...